Accurate Wealth Management LLC Has $244,000 Position in Elevance Health, Inc. (NYSE:ELV)

Accurate Wealth Management LLC reduced its stake in Elevance Health, Inc. (NYSE:ELV - Free Report) by 88.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 641 shares of the company's stock after selling 4,709 shares during the quarter. Accurate Wealth Management LLC's holdings in Elevance Health were worth $244,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of ELV. Cypress Wealth Services LLC increased its holdings in shares of Elevance Health by 3.5% during the third quarter. Cypress Wealth Services LLC now owns 679 shares of the company's stock valued at $353,000 after acquiring an additional 23 shares in the last quarter. Atomi Financial Group Inc. lifted its holdings in shares of Elevance Health by 4.2% in the third quarter. Atomi Financial Group Inc. now owns 615 shares of the company's stock worth $320,000 after buying an additional 25 shares in the last quarter. Lifeworks Advisors LLC boosted its stake in Elevance Health by 2.5% during the third quarter. Lifeworks Advisors LLC now owns 1,037 shares of the company's stock valued at $539,000 after buying an additional 25 shares during the last quarter. Catalyst Financial Partners LLC increased its position in Elevance Health by 2.9% in the third quarter. Catalyst Financial Partners LLC now owns 918 shares of the company's stock worth $477,000 after purchasing an additional 26 shares during the last quarter. Finally, Fullcircle Wealth LLC increased its position in Elevance Health by 1.5% in the third quarter. Fullcircle Wealth LLC now owns 1,743 shares of the company's stock worth $906,000 after purchasing an additional 26 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Stock Down 0.3 %

ELV traded down $1.00 during midday trading on Friday, hitting $384.26. 2,660,403 shares of the company's stock traded hands, compared to its average volume of 1,738,793. The company has a market cap of $89.12 billion, a PE ratio of 14.01, a price-to-earnings-growth ratio of 1.08 and a beta of 0.84. The stock's fifty day simple moving average is $388.79 and its 200-day simple moving average is $468.15. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.50 and a quick ratio of 1.50. Elevance Health, Inc. has a one year low of $362.21 and a one year high of $567.26.

Elevance Health (NYSE:ELV - Get Free Report) last released its earnings results on Thursday, October 17th. The company reported $8.37 earnings per share for the quarter, missing the consensus estimate of $9.66 by ($1.29). Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. The company had revenue of $44.72 billion during the quarter, compared to the consensus estimate of $43.47 billion. During the same quarter in the previous year, the business posted $8.99 EPS. The firm's quarterly revenue was up 5.3% on a year-over-year basis. As a group, equities analysts anticipate that Elevance Health, Inc. will post 32.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Raymond James set a $485.00 price target on shares of Elevance Health in a report on Friday, October 18th. Royal Bank of Canada lowered their price target on Elevance Health from $585.00 to $478.00 and set an "outperform" rating for the company in a research report on Friday, October 18th. Stephens reissued an "underperform" rating on shares of Elevance Health in a research note on Friday, October 18th. Argus lowered Elevance Health from a "buy" rating to a "hold" rating in a research report on Friday, October 18th. Finally, Truist Financial decreased their target price on Elevance Health from $520.00 to $480.00 and set a "buy" rating on the stock in a research report on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $536.53.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.